plasminogen

Plasminogen is a zymogen secreted as a precursor protein that, when cleaved by urokinase plasminogen activator (uPA) or tissue plasminogen activator (tPA), is converted into plasmin. Plasmin is a protease with broad specificity, capable of degrading fibrin and various extracellular matrix (ECM) components. Additionally, plasminogen functions as a proinflammatory regulator, promoting the healing of both acute and diabetic wounds. It is utilized in research related to wound healing, inflammation, and hypoplasminogenemia [1] [2].

Cenupatide acetate is an urokinase plasminogen activator receptor (uPAR) inhibitor for treating disorders associated altered cell migration, such as cancer.

LCKLSL acetate is a competitive annexin A2 (AnxA2) inhibitor. LCKLSL acetate potently inhibits the binding of tissue plasminogen activator (tPA) to AnxA2 and the generation of plasmin. LCKLSL acetate has anti-angiogenic roles.

Aprotinin (Traskolan) a broad-spectrum serine protease inhibitor, inhibiting the activity of a number of different esterases and proteases, including trypsin, chymotrypsin, kallikrein, plasmin, tissue plasminogen activator, and tissue and leukocytic proteinases.

Vitronectin, a multifunctional glycoprotein found in blood and the extracellular matrix, interacts with glycosaminoglycans, collagen, plasminogen, and the urokinase-receptor, in addition to stabilizing the inhibitory conformation of plasminogen activation inhibitor-1. It is utilized in research related to wound healing and tumor progression [1].

LCKLSL hydrochloride, an N-terminal hexapeptide and competitive annexin A2 (AnxA2) inhibitor, effectively disrupts the interaction between tissue plasminogen activator (tPA) and AnxA2. It additionally hinders plasmin generation and exhibits anti-angiogenic properties [1].

LCKLSL, an N-terminal hexapeptide, acts as a competitive inhibitor of annexin A2 (AnxA2), effectively preventing the binding of tissue plasminogen activator (tPA) to AnxA2 while also inhibiting the generation of plasmin. In addition, LCKLSL exhibits anti-angiogenic properties.

Cenupatide is a urokinase plasminogen activator receptor (uPAR) inhibitor. Cenupatide inhibits uPAR binding to the formyl peptide receptors (FPRs) can improve kidney lesions in a rat model of STZ-induced diabetes. Cenupatide reverted STZ-induced up-regula

Z-Gly-Gly-Arg-AFC, also known as a plasminogen activator acrosine substrate with fluorescence, is a biologically active peptide.